v3.26.1
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting
The following table illustrates information about segment revenues, significant segment expenses, and segment net income (loss) for the three and six months ended June 30, 2026 and 2025:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenues$218,250 $163,353 $374,663 $308,887 
Less1:
Cost of product sales3,840 2,798 9,217 7,366 
Acquired in-process research and development— — 697,761 — 
Research and development (excluding stock-based compensation)
Navenibart17,328 — 27,069 — 
BCX177255,240 3,316 7,147 5,772 
Berotralstat1,611 4,766 3,407 6,640 
Avoralstat351 3,305 1,244 5,784 
STAR-031091 — 774 — 
Research, discovery and preclinical programs3,441 3,560 7,411 6,604 
Compensation and related personnel costs11,390 12,369 38,481 24,712 
Other non-program specific and indirect costs7,044 6,743 14,463 13,289 
Sales and marketing (excluding stock-based compensation)33,947 45,589 76,900 93,259 
General and administrative (excluding stock-based compensation)20,810 29,817 63,203 51,776 
Stock-based compensation14,692 21,304 30,719 42,672 
Interest income(2,434)(2,516)(4,690)(5,540)
Interest expense21,712 21,582 41,491 45,076 
Foreign currency (gains) losses(27)63 198 62 
Loss on extinguishment of debt— 4,171 — 4,171 
Other (income) expense, net(260)— 1,202 — 
Income tax expense1,079 1,401 2,083 2,127 
Consolidated net income (loss)
$78,395 $5,085 $(643,417)$5,117 
1 The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.